

National Cancer Research Institute (NCRI)

NCRI Groups

Remit of NCRI Groups

Version 10.0 - February 2019



Each NCRI Group has a UK-wide strategic remit to:

- Develop and maintain a comprehensive national portfolio of clinical trials and other well-designed studies:
 - including, but not limited to, large-scale pragmatic trials, international trials and studies in health service research
 - encompassing both academic and industry sponsored trials
 - proposed by NCRI Group members and individuals outside of the NCRI Group membership
 - including international trials
- Foster translational research in the trial portfolio that enhances the potential for stratified medicine
- Liaise with funding bodies in order to:
 - secure funding for the above mentioned portfolio of clinical trials
 - provide written comments on application submissions
- Interact with:
 - the NCRI Cancer Clinical Trials Unit (CTU) Group members to optimise development of the UKs cancer trials portfolio
 - other site-specific and cross-cutting NCRI Groups as appropriate
 - the ECMCs and early phase clinical trials groups
 - the UK clinical research networks (including the devolved nations) to optimise delivery of cancer clinical trials, playing a role specifically in troubleshooting for problematic trials
- Consider views and advice provided by consumer representatives
- Add an expert voice to the development of national initiatives, strategic partnerships and national consultations relevant to cancer clinical trials (e.g. NICE, the NCRI Board)
- Be responsible for the membership and activities of its subgroups
- Engage with the NCRI Group Annual Review process and the International Quinquennial Review process